(Q44146948)

30 November 2017

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial (English)

1 reference

30 November 2017

1 reference

J Cuzick

1

1 reference

30 November 2017

J Forbes

2

1 reference

30 November 2017

R Edwards

3

1 reference

30 November 2017

M Baum

4

1 reference

30 November 2017

S Cawthorn

5

1 reference

30 November 2017

A Coates

6

1 reference

30 November 2017

A Hamed

7

1 reference

30 November 2017

A Howell

8

1 reference

30 November 2017

T Powles

9

1 reference

30 November 2017

IBIS investigators

10

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

30 November 2017

1 reference

30 November 2017

360

1 reference

30 November 2017

817-824

1 reference

30 November 2017

9336

1 reference

'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

Tamoxifen and contralateral breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

The prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

A brief review of the current breast cancer prevention trials and proposals for future trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909962-2

7 January 2021

10.1016/S0140-6736(02)09962-2

Identifiers

DOI

1 reference

30 November 2017

1 reference